Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.

NCT00600249 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT00600249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.
Lead sponsor
Centre Jean Perrin
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
May 31, 2012
Enrollment
35 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer